Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2012 Feb 01;812:134-42. doi: 10.1124/mol.111.074823.
Show Gene links
Show Anatomy links
Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1).
Visentin M
,
Chang MH
,
Romero MF
,
Zhao R
,
Goldman ID
.
???displayArticle.abstract???
Human organic anion-transporting polypeptide (OATP) 2B1 (OATP-B; SLCO2B1) is expressed in the apical membrane of the small intestine and the hepatocyte basolateral membrane and transports structurally diverse organic anions with a wide spectrum of pH sensitivities. This article describes highly pH-dependent OATP2B1-mediated antifolate transport and compares this property with that of sulfobromophthalein (BSP), a preferred OATP2B1 substrate. At pH 5.5 and low substrate concentrations (~2.5 μM), only [(3)H]pemetrexed influx [in contrast to methotrexate (MTX), folic acid, and reduced folates] could be detected in OATP2B1-transfected HeLa R1-11 cells that lack endogenous folate-specific transporters. Influx was optimal at pH 4.5 to 5.5, falling precipitously with an increase in pH >6.0; BSP influx was independent of pH. Influx of both substrates at low pH was markedly inhibited by the proton ionophore 4-(trifluoromethoxy)phenylhydrazone; BSP influx was also suppressed at pH 7.4. At 300 μM MTX, influx was one-third that of pemetrexed; influx of folic acid, (6S)5-methyltetrahydrofolate, or (6S)5-formyltetrahydrofolate was not detected. There were similar findings in OATP2B1-expressing Xenopus laevis oocytes. The pemetrexed influx K(m) was ~300 μM; the raltitrexed influx K(i) was ~70 μM at pH 5.5. Stable expression of OAPT2B1 in HeLa R1-11 cells resulted in substantial raltitrexed, but modest pemetrexed, growth inhibition consistent with their affinities for this carrier. Hence, OATP2B1 represents a low-affinity transport route for antifolates (relative affinities: raltitrexed > pemetrexed > MTX) at low pH. In contrast, the high affinity of this transporter for BSP relative to antifolates seems to be intrinsic to its binding site and independent of the proton concentration.
Abe,
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.
2001, Pubmed,
Xenbase
Abe,
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.
2001,
Pubmed
,
Xenbase
Al Sarakbi,
The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
2006,
Pubmed
Assaraf,
Molecular basis of antifolate resistance.
2007,
Pubmed
Badagnani,
Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants.
2006,
Pubmed
,
Xenbase
Benz,
The molecular mechanism of action of the proton ionophore FCCP (carbonylcyanide p-trifluoromethoxyphenylhydrazone).
1983,
Pubmed
Diop-Bove,
Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line.
2009,
Pubmed
Goldman,
The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
2010,
Pubmed
Grube,
Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart.
2006,
Pubmed
Hagenbuch,
Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties.
2004,
Pubmed
Hayeshi,
Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories.
2008,
Pubmed
Kato,
Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport.
2010,
Pubmed
,
Xenbase
Kobayashi,
Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.
2003,
Pubmed
Kullak-Ublick,
Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.
2001,
Pubmed
,
Xenbase
Leuthold,
Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters.
2009,
Pubmed
,
Xenbase
Matherly,
Membrane transport of folates.
2003,
Pubmed
Matherly,
Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter.
2008,
Pubmed
Mita,
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
2006,
Pubmed
Nakai,
Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter.
2007,
Pubmed
Nozawa,
Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.
2004,
Pubmed
Qiu,
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
2006,
Pubmed
,
Xenbase
Rizwan,
Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.
2007,
Pubmed
Romero,
Cloning and functional expression of rNBC, an electrogenic Na(+)-HCO3- cotransporter from rat kidney.
1998,
Pubmed
,
Xenbase
Sai,
Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells.
2006,
Pubmed
Sharif,
Rapid determination of membrane transport parameters in adherent cells.
2000,
Pubmed
Takeda,
Characterization of methotrexate transport and its drug interactions with human organic anion transporters.
2002,
Pubmed
Tamai,
Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C.
2001,
Pubmed
,
Xenbase
Tamai,
Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.
2000,
Pubmed
Tannock,
Acid pH in tumors and its potential for therapeutic exploitation.
1989,
Pubmed
Unal,
The functional roles of the His247 and His281 residues in folate and proton translocation mediated by the human proton-coupled folate transporter SLC46A1.
2009,
Pubmed
,
Xenbase
Uwai,
Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate.
2010,
Pubmed
,
Xenbase
Wang,
Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
2004,
Pubmed
Wang,
Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.
2010,
Pubmed
Wright,
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
2011,
Pubmed
Zhao,
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
2000,
Pubmed
Zhao,
The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.
2008,
Pubmed
,
Xenbase
Zhao,
Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
2004,
Pubmed
Zhao,
Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.
2009,
Pubmed
Zhao,
Mechanisms of membrane transport of folates into cells and across epithelia.
2011,
Pubmed
Zhao,
Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells.
2001,
Pubmed
